Turn Therapeutics (TTRX) Competitors

Turn Therapeutics logo
$8.55 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$9.15 +0.60 (+6.99%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TTRX vs. URGN, CRON, ANRO, AMPH, and CALT

Should you buy Turn Therapeutics stock or one of its competitors? Turn Therapeutics's main competitors and comparable companies include Urogen Pharma (URGN), Cronos Group (CRON), Alto Neuroscience (ANRO), Amphastar Pharmaceuticals (AMPH), and Calliditas Therapeutics AB (publ) (CALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Turn Therapeutics compare to Urogen Pharma?

Turn Therapeutics (NASDAQ:TTRX) and Urogen Pharma (NASDAQ:URGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Urogen Pharma had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 3 mentions for Urogen Pharma and 2 mentions for Turn Therapeutics. Urogen Pharma's average media sentiment score of 1.23 beat Turn Therapeutics' score of 0.48 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Turn Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Urogen Pharma
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Turn Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Turn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turn TherapeuticsN/AN/A-$3.19M-$0.43N/A
Urogen Pharma$250.25M5.70-$153.49M-$1.32N/A

91.3% of Urogen Pharma shares are owned by institutional investors. 55.9% of Turn Therapeutics shares are owned by insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Turn Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 10.69%. Urogen Pharma has a consensus price target of $53.38, suggesting a potential upside of 83.47%. Given Urogen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Urogen Pharma is more favorable than Turn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turn Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.67
Urogen Pharma
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Turn Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -26.27%. Urogen Pharma's return on equity of 0.00% beat Turn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Turn TherapeuticsN/A -261.87% -70.18%
Urogen Pharma -26.27%N/A -26.88%

Summary

Urogen Pharma beats Turn Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to Cronos Group?

Turn Therapeutics (NASDAQ:TTRX) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

8.7% of Cronos Group shares are held by institutional investors. 55.9% of Turn Therapeutics shares are held by insiders. Comparatively, 7.8% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Turn Therapeutics has higher earnings, but lower revenue than Cronos Group. Turn Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turn TherapeuticsN/AN/A-$3.19M-$0.43N/A
Cronos Group$146.59M8.04-$9.45M$0.1718.91

Cronos Group has a net margin of 28.04% compared to Turn Therapeutics' net margin of 0.00%. Cronos Group's return on equity of 2.56% beat Turn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Turn TherapeuticsN/A -261.87% -70.18%
Cronos Group 28.04%2.56%2.43%

Turn Therapeutics currently has a consensus price target of $9.00, indicating a potential upside of 10.69%. Cronos Group has a consensus price target of $2.30, indicating a potential downside of 28.46%. Given Turn Therapeutics' higher probable upside, equities research analysts clearly believe Turn Therapeutics is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turn Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.67
Cronos Group
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Cronos Group had 4 more articles in the media than Turn Therapeutics. MarketBeat recorded 6 mentions for Cronos Group and 2 mentions for Turn Therapeutics. Cronos Group's average media sentiment score of 1.68 beat Turn Therapeutics' score of 0.48 indicating that Cronos Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Turn Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cronos Group
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Cronos Group beats Turn Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Alto Neuroscience's return on equity of -41.82% beat Turn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alto NeuroscienceN/A -41.82% -36.56%
Turn Therapeutics N/A -261.87%-70.18%

In the previous week, Alto Neuroscience had 23 more articles in the media than Turn Therapeutics. MarketBeat recorded 25 mentions for Alto Neuroscience and 2 mentions for Turn Therapeutics. Alto Neuroscience's average media sentiment score of 0.74 beat Turn Therapeutics' score of 0.48 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alto Neuroscience
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Turn Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Turn Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alto NeuroscienceN/AN/A-$63.24M-$2.44N/A
Turn TherapeuticsN/AN/A-$3.19M-$0.43N/A

Alto Neuroscience currently has a consensus price target of $37.88, indicating a potential upside of 49.61%. Turn Therapeutics has a consensus price target of $9.00, indicating a potential upside of 10.69%. Given Alto Neuroscience's higher possible upside, equities research analysts plainly believe Alto Neuroscience is more favorable than Turn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alto Neuroscience
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Turn Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.67

Summary

Alto Neuroscience beats Turn Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Turn Therapeutics compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Amphastar Pharmaceuticals has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amphastar Pharmaceuticals$745.79M1.67$98.09M$2.1913.30
Turn TherapeuticsN/AN/A-$3.19M-$0.43N/A

Amphastar Pharmaceuticals has a net margin of 13.27% compared to Turn Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.31% beat Turn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amphastar Pharmaceuticals13.27% 15.31% 7.15%
Turn Therapeutics N/A -261.87%-70.18%

Amphastar Pharmaceuticals presently has a consensus target price of $23.33, indicating a potential downside of 19.89%. Turn Therapeutics has a consensus target price of $9.00, indicating a potential upside of 10.69%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Turn Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amphastar Pharmaceuticals
1 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.88
Turn Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.67

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 55.9% of Turn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 3 mentions for Amphastar Pharmaceuticals and 2 mentions for Turn Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.98 beat Turn Therapeutics' score of 0.48 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amphastar Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Turn Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Amphastar Pharmaceuticals beats Turn Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Turn Therapeutics has a consensus target price of $9.00, indicating a potential upside of 10.69%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Turn Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Turn Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.67

In the previous week, Turn Therapeutics had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Turn Therapeutics' average media sentiment score of 0.48 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
Turn Therapeutics Neutral

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 55.9% of Turn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Turn Therapeutics has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Turn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
Turn TherapeuticsN/AN/A-$3.19M-$0.43N/A

Turn Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Turn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
Turn Therapeutics N/A -261.87%-70.18%

Summary

Turn Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTRX vs. The Competition

MetricTurn TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$261.40M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E RatioN/A29.4034.1729.86
Price / SalesN/A7.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book45.005.114.373.66
Net Income-$3.19M$2.88B$3.52B$392.27M
7 Day Performance-13.81%-4.10%-5.47%-4.73%
1 Month Performance-19.11%-5.08%-4.57%-7.14%
1 Year Performance144.29%-7.47%-1.79%-7.51%

Turn Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTRX
Turn Therapeutics
1.5412 of 5 stars
$8.55
flat
$9.00
+5.3%
+113.8%$261.40MN/AN/A2
URGN
Urogen Pharma
3.7381 of 5 stars
$26.39
+1.1%
$53.38
+102.3%
+18.3%$1.28B$109.79MN/A291
CRON
Cronos Group
2.6993 of 5 stars
$3.41
-1.2%
$2.30
-32.6%
+33.5%$1.26B$146.59M43.12610
ANRO
Alto Neuroscience
2.0605 of 5 stars
$30.77
-1.2%
$37.88
+23.1%
+125.3%$1.25BN/AN/A68
AMPH
Amphastar Pharmaceuticals
1.5281 of 5 stars
$28.87
+0.9%
$23.33
-19.2%
+11.9%$1.22B$719.89M10.671,976

Related Companies and Tools


This page (NASDAQ:TTRX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners